Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43580| Title: | Sjogren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient | Authors: | Caeyman, Aaron Vandekerckhove, Olivia Pat, Karin Wynants, Jokke Weytjens, Karolien de Wergifosse, Isabelle CUPPENS, Kristof |
Issue Date: | 2023 | Publisher: | KARGER | Source: | Case reports in oncology, 16 (1) , p. 1095 -1099 | Abstract: | In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjogren's syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab). | Notes: | Cuppens, K (corresponding author), Jessa Hosp, Dept Resp Med & Thorac Oncol, Hasselt, Belgium. Kristof.cuppens@jessazh.be |
Keywords: | Sjogren's syndrome: Sicca syndrome;Pembrolizum;abImmune checkpoint inhibition;Non-small cell lung carcinoma;Immune-related adverse event;Case report | Document URI: | http://hdl.handle.net/1942/43580 | ISSN: | 1662-6575 | e-ISSN: | 1662-6575 | DOI: | 10.1159/000532098 | ISI #: | 001203472100147 | Rights: | 2023 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient.pdf | Published version | 374.2 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.